Aquestive Therapeutics Inc (AQST) — Cash Flow-to-Debt Ratio
Aquestive Therapeutics Inc (AQST) has a Cash Flow-to-Debt Ratio of -0.08x as of March 2026, meaning its operating cash flow of $-14.81 Million could theoretically repay 0% of its total liabilities ($175.18 Million) in one year. Explore long-term investment intensity of Aquestive Therapeutics Inc to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aquestive Therapeutics Inc Cash Flow-to-Debt Ratio (2005–2025)
Historical debt coverage capacity for Aquestive Therapeutics Inc across 12 annual periods. Also explore Aquestive Therapeutics Inc asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Aquestive Therapeutics Inc (2005–2025)
Year-by-year debt coverage analysis for Aquestive Therapeutics Inc. For market capitalisation and broader financial context, see market cap of Aquestive Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.27x | $-52.43 Million | $194.09 Million | ▼ -22.1% |
| 2024 | -0.22x | $-35.76 Million | $161.58 Million | ▼ -468.6% |
| 2023 | -0.04x | $-6.38 Million | $163.91 Million | ▲ +30.2% |
| 2022 | -0.06x | $-9.79 Million | $175.62 Million | ▲ +75.6% |
| 2021 | -0.23x | $-32.98 Million | $144.13 Million | ▲ +43.9% |
| 2020 | -0.41x | $-45.46 Million | $111.38 Million | ▲ +42.7% |
| 2019 | -0.71x | $-60.21 Million | $84.60 Million | ▼ -320.6% |
| 2018 | -0.17x | $-12.99 Million | $76.77 Million | ▼ -302.3% |
| 2017 | 0.08x | $5.82 Million | $69.61 Million | ▲ +158.3% |
| 2016 | -0.14x | $-8.18 Million | $56.97 Million | ▲ +97.0% |
| 2006 | -4.83x | $-9.26 Million | $1.92 Million | ▼ -477.2% |
| 2005 | -0.84x | $-6.39 Million | $7.64 Million | — |